Waxy- or Putty-Like Materials as a Novel Drug Preparation for Synthetic Cannabinoid Receptor Agonists: Detection in Prisons and In Vitro Cannabinoid Receptor Activity.
CB1 receptor bioassay
MDMB‐INACA
new psychoactive substances (NPS)
novel drug preparations
synthetic cannabinoid receptor agonists (SCRAs)
Journal
Drug testing and analysis
ISSN: 1942-7611
Titre abrégé: Drug Test Anal
Pays: England
ID NLM: 101483449
Informations de publication
Date de publication:
15 Oct 2024
15 Oct 2024
Historique:
revised:
23
09
2024
received:
12
07
2024
accepted:
24
09
2024
medline:
16
10
2024
pubmed:
16
10
2024
entrez:
16
10
2024
Statut:
aheadofprint
Résumé
After the Scottish Prison Service (SPS) introduced mail photocopying procedures in December 2021, a shift in smuggling methods was observed for synthetic cannabinoid receptor agonists (SCRAs) and other new psychoactive substances (NPS) from drug-infused papers back to traditional sample matrices (e.g., tablets and powders), although new matrices also emerged. This study reports on waxy- or putty-like materials as a novel drug preparation for SCRAs and other drugs seized from UK prisons. In 2023, 22 of these new preparations were seized from Scottish prisons, with eight found in sealed vape pods. The materials were positive for SCRAs, phytocannabinoids, novel benzodiazepines, and/or gabapentinoids. Additionally, 11 preparations were seized from an English prison, all containing the SCRAs MDMB-4en-PINACA and MDMB-INACA. MDMB-INACA was pharmacologically characterized using in vitro CB
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Scottish Prison Service
Organisme : Leverhulme Trust
ID : RC-2015-011
Organisme : Bijzonder Onderzoeksfonds (BOF) of Ghent University
ID : BOF21/DOC/248
Organisme : Research Foundation Flanders
ID : 1S54521N
Organisme : Engineering and Physical Sciences Research Council
ID : EP/V026917/1
Organisme : Engineering and Physical Sciences Research Council
ID : EP/L016354/1
Organisme : Strategic Research Area in Forensic Sciences at Linköping University
Informations de copyright
© 2024 The Author(s). Drug Testing and Analysis published by John Wiley & Sons Ltd.
Références
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), European Drug Report 2024: Trends and Developments (Luxembourg: Publications Office of the European Union, 2024), https://doi.org/10.2810/91693.
S. D. Banister and M. Connor, “The Chemistry and Pharmacology of Synthetic Cannabinoid Receptor Agonists as New Psychoactive Substances: Origins,” in New Psychoactive Substances, Handbook of Experimental Pharmacology, vol. 252, eds. H. H. Maurer and S. D. Brandt (Cham, Switzerland: Springer International Publishing AG, 2018), 165–190, https://doi.org/10.1007/164_2018_143.
S. D. Banister and M. Connor, “The Chemistry and Pharmacology of Synthetic Cannabinoid Receptor Agonists as New Psychoactive Substances: Evolution,” in New Psychoactive Substances, Handbook of Experimental Pharmacology, vol. 252, eds. H. H. Maurer and S. Brandt (Cham, Switzerland: Springer International Publishing AG, 2018), 191–226, https://doi.org/10.1007/164_2018_144.
K. E. Grafinger, A. Cannaert, A. Ametovski, et al., “Systematic Evaluation of a Panel of 30 Synthetic Cannabinoid Receptor Agonists Structurally Related to MMB‐4en‐PICA, MDMB‐4en‐PINACA, ADB‐4en‐PINACA, and MMB‐4CN‐BUTINACA Using a Combination of Binding and Different CB1 Receptor Activation Assays—Part II,” Drug Testing and Analysis 13 (2021): 1402–1411, https://doi.org/10.1002/dta.3035.
M. S. Castaneto, D. A. Gorelick, N. A. Desrosiers, R. L. Hartman, S. Pirard, and M. A. Huestis, “Synthetic Cannabinoids: Epidemiology, Pharmacodynamics, and Clinical Implications,” Drug and Alcohol Dependence 144 (2014): 12–41, https://doi.org/10.1016/j.drugalcdep.2014.08.005.
A. Giorgetti, F. P. Busardò, R. Tittarelli, V. Auwärter, and R. Giorgetti, “Post‐Mortem Toxicology: A Systematic Review of Death Cases Involving Synthetic Cannabinoid Receptor Agonists,” Frontiers in Psychiatry 11 (2020): 1–22, https://doi.org/10.3389/fpsyt.2020.00464.
B. Pulver, S. Fischmann, A. Gallegos, and R. Christie, “EMCDDA Framework and Practical Guidance for Naming Synthetic Cannabinoids,” Drug Testing and Analysis 15 (2022): 255–276, https://doi.org/10.1002/dta.3403.
United Nations Office on Drugs and Crime (UNODC), May 2021—China: Announcement to Place Synthetic Cannabinoids under Generic Control, 2021, https://www.unodc.org/LSS/Announcement/Details/ff032a29‐2e14‐4dab‐b7d8‐ab86d355c809#:~:text=BEIJING%2C%20China%20%E2%80%93%20May%202021%3A,using%20an%20individual%20listing%20approach.
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), EU Early Warning System Formal Notification. [Notification of MDMB‐INACA in Europe] EU‐EWS‐RCS‐FN‐2022‐0026. 2022.
C. Richeval, A. Gish, V. Cottereau, et al., “A Current Overview of the Pharmacological Composition of “La Chimique” Consumed in Mayotte: Preliminary Results of the CHASSE‐MAREE Protocol,” Drug Testing and Analysis 16 (2023): 1–12, https://doi.org/10.1002/dta.3585.
A. J. Krotulski, N. Lattanzio, B. McGinty, S. E. Walton, M. F. Fogarty, and B. K. Logan, MDMB‐INACA—NPS Discovery New Drug Monograph (Willow Grove, Pennsylvania: Center for Forensic Science Research and Education, 2023), https://www.cfsre.org/images/monographs/MDMB‐INACA‐New‐Drug‐Monograph‐NPS‐Discovery‐230626.pdf.
New Zealand National Drug Intelligence Bureau, Request for a Temporary Class Drug Order: ADB‐5Br‐INACA, MDMB‐5Br‐INACA, and MDMB‐INACA, 2022, https://www.health.govt.nz/system/files/documents/pages/tcdo_request_‐_adb‐5br‐inaca_mdmb‐5br‐inaca_and_mdmb‐inaca.pdf.
C. Norman, K. Webling, O. Kyslychenko, et al., “Detection in Seized Samples, Analytical Characterization, and In Vitro Metabolism of the Newly Emerged 5‐Bromo‐Indazole_3‐Carboxamide Synthetic Cannabinoid Receptor Agonists,” Drug Testing and Analysis 16 (2023): 915–935, https://doi.org/10.1002/dta.3609.
M. H. Deventer, M. Persson, C. Norman, et al., “In Vitro Cannabinoid Activity Profiling of Generic Ban‐Evading Brominated Synthetic Cannabinoid Receptor Agonists and Their Analogs,” Drug Testing and Analysis 16 (2023): 616–628, https://doi.org/10.1002/dta.3592.
China Pharmaceutical University, Hapten for Synthesizing Cannabinoid ADB‐BUTINACA, Monoclonal Antibody and Application Thereof, 2024, CN118063385A.
R. Andrews, R. Jorge, R. Christie, and A. Gallegos, “From JWH‐018 to OXIZIDS: Structural Evolution of Synthetic Cannabinoids in the European Union From 2008 to Present Day,” Drug Testing and Analysis 15 (2023): 378–387, https://doi.org/10.1002/dta.3422.
J. A. Hvozdovich, C. W. Chronister, B. K. Logan, and B. A. Goldberger, “Case Report: Synthetic Cannabinoid Deaths in State of Florida Prisoners,” Journal of Analytical Toxicology 44 (2020): 298–300, https://doi.org/10.1093/jat/bkz092.
R. Ralphs, L. Williams, R. Askew, and A. Norton, “Adding Spice to the Porridge: The Development of a Synthetic Cannabinoid Market in an English Prison,” International Journal on Drug Policy 40 (2017): 57–69, https://doi.org/10.1016/j.drugpo.2016.10.003.
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), New Psychoactive Substances in Prison: Results From an EMCDDA Trendspotter Study (Luxembourg: Publications Office of the European Union, 2018), https://doi.org/10.2810/492880.
G. Vaccaro, A. Massariol, A. Guirguis, S. B. Kirton, and J. L. Stair, “NPS Detection in Prison: A Systematic Literature Review of use, Drug Form, and Analytical Approaches,” Drug Testing and Analysis 14 (2022): 1350–1367, https://doi.org/10.1002/dta.3263.
C. Norman, “A Global Review of Prison Drug Smuggling Routes and Trends in the Usage of Drugs in Prisons,” WIREs Forensic Science 5 (2023): 1–33, https://doi.org/10.1002/wfs2.1473.
E. Van Dyken, F. Y. Lai, P. K. Thai, et al., “Challenges and Opportunities in Using Wastewater Analysis to Measure Drug use in a Small Prison Facility,” Drug and Alcohol Review 35 (2016): 138–147, https://doi.org/10.1111/dar.12156.
C. Norman, G. Walker, B. McKirdy, et al., “Detection and Quantitation of Synthetic Cannabinoid Receptor Agonists in Infused Papers From Prisons in a Constantly Evolving Illicit Market,” Drug Testing and Analysis 12 (2020): 538–554, https://doi.org/10.1002/dta.2767.
J. Caterino, J. Clark, and J. C. Yohannan, “Analysis of Synthetic Cannabinoids on Paper Before and After Processing for Latent Print Using DFO and Ninhydrin,” Forensic Science International 305 (2019): 1–5, https://doi.org/10.1016/j.forsciint.2019.110000.
L. T. Ford and J. D. Berg, “Analytical Evidence to Show Letters Impregnated With Novel Psychoactive Substances Are a Means of Getting Drugs to Inmates Within the UK Prison Service,” Annals of Clinical Biochemistry 55 (2018): 673–678, https://doi.org/10.1177/0004563218767462.
T. B. Rodrigues, M. P. Souza, L. de Melo Barbosa, et al., “Synthetic Cannabinoid Receptor Agonists Profile in Infused Papers Seized in Brazilian Prisons,” Forensic Toxicology 40 (2022): 119–124, https://doi.org/10.1007/s11419‐021‐00586‐7.
V. Marland, R. Reid, A. M. Brandon, et al., “Changing Trends in Novel Benzodiazepine use Within Scottish Prisons: Detection, Quantitation, Prevalence, and Modes of use,” Drug Testing and Analysis 16 (2024): 457–472, https://doi.org/10.1002/dta.3560.
A. Giorgetti, P. Brunetti, S. Pelotti, and V. Auwärter, “Detection of AP‐237 and Synthetic Cannabinoids on an Infused Letter Sent to a German Prisoner,” Drug Testing and Analysis 14 (2022): 1779–1784, https://doi.org/10.1002/dta.3351.
P. Gray and R. Ralphs, “Harm Reduction or a Catalyst for New Harms? The Impact of Smoke‐Free Prison Policy on Prisoners and the Prison Regime,” Prison Service Journal 254 (2021): 39–45, https://www.crimeandjustice.org.uk/sites/crimeandjustice.org.uk/files/PSJ%20254%20May%202021.pdf.
Cowan D, Photocopying Prisoners' Mail “Leads to Cut in Drug Overdoses,” BBC Scotland, 2022, https://www.bbc.co.uk/news/uk‐scotland‐59972295.
M. Loflin and M. Earleywine, “A New Method of Cannabis Ingestion: The Dangers of Dabs?,” Addictive Behaviors 39 (2014): 1430–1433, https://doi.org/10.1016/j.addbeh.2014.05.013.
M. C. Meacham, M. J. Paul, and D. E. Ramo, “Understanding Emerging Forms of Cannabis Use Through an Online Cannabis Community: An Analysis of Relative Post Volume and Subjective Highness Ratings,” Drug and Alcohol Dependence 188 (2018): 364–369, https://doi.org/10.1016/j.drugalcdep.2018.03.041.
M. H. Meier, “Associations Between Butane Hash Oil Use and Cannabis‐Related Problems,” Drug and Alcohol Dependence 179 (2017): 25–31, https://doi.org/10.1016/j.drugalcdep.2017.06.015.
N. Seltenrich, “Cannabis Contaminants: Regulating Solvents, Microbes, and Metals in Legal Weed,” Environmental Health Perspectives 127 (2019): 1–6, https://doi.org/10.1289/EHP5785.
J. M. Stogner and B. L. Miller, “The Dabbing Dilemma: A Call for Research on Butane Hash Oil and Other Alternate Forms of Cannabis Use,” Substance Abuse 36 (2015): 393–395, https://doi.org/10.1080/08897077.2015.1071724.
R. P. Anderson and K. Zechar, “Lung Injury From Inhaling Butane Hash oil Mimics Pneumonia,” Respiratory Medicine Case Reports 26 (2019): 171–173, https://doi.org/10.1016/j.rmcr.2019.01.002.
L. H. Antonides, A. Cannaert, C. Norman, et al., “Shape Matters: The Application of Activity‐Based In Vitro Bioassays and Chiral Profiling to the Pharmacological Evaluation of Synthetic Cannabinoid Receptor Agonists in Drug‐Infused Papers Seized in Prisons,” Drug Testing and Analysis 13 (2020): 628–643, https://doi.org/10.1002/dta.2965.
R. Kronstrand, C. Norman, S. Vikingsson, et al., “The Metabolism of the Synthetic Cannabinoids ADB‐BUTINACA and ADB‐4en‐PINACA and Their Detection in Forensic Toxicology Casework and Infused Papers Seized in Prisons,” Drug Testing and Analysis 14 (2022): 634–652, https://doi.org/10.1002/dta.3203.
“HighResNPS,” accessed August 22, 2024, highresnps.com.
M. Mardal, M. F. Andreasen, C. B. Mollerup, et al., “HighResNPS.com: An Online Crowd‐Sourced HR‐MS Database for Suspect and Non‐targeted Screening of New Psychoactive Substances,” Journal of Analytical Toxicology 43 (2019): 520–527, https://doi.org/10.1093/jat/bkz030.
H. A. Naqi, T. J. Woodman, S. M. Husbands, and I. S. Blagbrough, “19F and 1H Quantitative‐NMR Spectroscopic Analysis of Fluorinated Third‐Generation Synthetic Cannabinoids,” Analytical Methods 11 (2019): 3090–3100, https://doi.org/10.1039/c9ay00814d.
M. H. Deventer, K. Van Uytfanghe, I. M. J. Vinckier, F. Reniero, C. Guillou, and C. P. Stove, “Cannabinoid Receptor Activation Potential of the Next Generation, Generic Ban Evading OXIZID Synthetic Cannabinoid Receptor Agonists,” Drug Testing and Analysis 14 (2022): 1565–1575, https://doi.org/10.1002/dta.3283.
E. Sparkes, A. Timmerman, J. W. Markham, et al., “Synthesis and Functional Evaluation of Synthetic Cannabinoid Receptor Agonists Related to ADB‐HEXINACA,” ACS Chemical Neuroscience 15 (2024): 1787–1812, https://doi.org/10.1021/acschemneuro.3c00818.
A. Cannaert, J. Storme, F. Franz, V. Auwärter, and C. P. Stove, “Detection and Activity Profiling of Synthetic Cannabinoids and Their Metabolites With a Newly Developed Bioassay,” Analytical Chemistry 88 (2016): 11476–11485, https://doi.org/10.1021/acs.analchem.6b02600.
A. Cannaert, F. Franz, V. Auwärter, and C. P. Stove, “Activity‐Based Detection of Consumption of Synthetic Cannabinoids in Authentic Urine Samples Using a Stable Cannabinoid Reporter System,” Analytical Chemistry 89 (2017): 9527–9536, https://doi.org/10.1021/acs.analchem.7b02552.
A. Cannaert, J. Storme, C. Hess, V. Auwärter, S. M. R. Wille, and C. P. Stove, “Activity‐Based Detection of Cannabinoids in Serum and Plasma Samples,” Clinical Chemistry 64 (2018): 918–926, https://doi.org/10.1373/clinchem.2017.285361.
P. García‐Atienza, F. A. Esteve‐Turrillas, and S. Armenta, “Evaluation of the In‐Vitro Inhalation Uptake of MDMB‐4en‐PINACA Using a Smoking Simulation Chamber,” Microchemical Journal 181 (2022): 1–6, https://doi.org/10.1016/j.microc.2022.107737.
S. Deeb, F. M. Wylie, H. J. Torrance, and K. S. Scott, “An Insight Into Gabapentin and Pregabalin in Scottish Prisoners,” Journal of Analytical Toxicology 44 (2020): 504–513, https://doi.org/10.1093/jat/bkz105.
M. Longworth, M. Connor, S. D. Banister, and M. Kassiou, “Synthesis and Pharmacological Profiling of the Metabolites of Synthetic Cannabinoid Drugs APICA, STS‐135, ADB‐PINACA, and 5F‐ADB‐PINACA,” ACS Chemical Neuroscience 8 (2017): 1673–1680, https://doi.org/10.1021/acschemneuro.7b00116.
A. Asada, T. Doi, T. Tagami, et al., “Cannabimimetic Activities of Cumyl Carboxamide‐Type Synthetic Cannabinoids,” Forensic Toxicology 36 (2018): 170–177, https://doi.org/10.1007/s11419‐017‐0374‐9.
S. Münster‐Müller, S. Hansen, T. Opatz, R. Zimmermann, and M. Pütz, “Chemical Profiling of the Synthetic Cannabinoid MDMB‐CHMICA: Identification, Assessment, and Stability Study of Synthesis‐Related Impurities in Seized and Synthesized Samples,” Drug Testing and Analysis 11 (2019): 1192–1206, https://doi.org/10.1002/dta.2652.
I. Al‐Zouabi, J. M. Stogner, B. L. Miller, and E. S. Lane, “Butane Hash Oil and Dabbing: Insights Into Use, Amateur Production Techniques, and Potential Harm Mitigation,” Substance Abuse and Rehabilitation 9 (2018): 91–101, https://doi.org/10.2147/sar.s135252.
G. C. K. Chan, W. Hall, T. P. Freeman, J. Ferris, A. B. Kelly, and A. Winstock, “User Characteristics and Effect Profile of Butane Hash Oil: An Extremely High‐Potency Cannabis Concentrate,” Drug and Alcohol Dependence 178 (2017): 32–38, https://doi.org/10.1016/j.drugalcdep.2017.04.014.
G. Jensen, R. Bertelotti, D. Greenhalgh, T. Palmieri, and P. Maguina, “Honey Oil Burns: A Growing Problem,” Journal of Burn Care & Research 36 (2015): e34–e37, https://doi.org/10.1097/BCR.0000000000000067.
D. Stephens, J. K. Patel, D. Angelo, and J. Frunzi, “Cannabis Butane Hash Oil Dabbing Induced Lung Injury Mimicking Atypical Pneumonia,” Cureus 12 (2020): 10–13, https://doi.org/10.7759/cureus.7033.
A. Ahmed, D. Shapiro, J. Su, and L. P. Nelson, “Vaping Cannabis Butane Hash Oil Leads to Severe Acute Respiratory Distress Syndrome—A Case of EVALI in a Teenager With Hypertrophic Cardiomyopathy,” Journal of Intensive Care Medicine 36 (2021): 617–621, https://doi.org/10.1177/0885066620941004.
M. J. McMahon, N. A. Bhatt, C. G. Stahlmann, and A. I. Philip, “Severe Pneumonitis After Inhalation of Butane Hash Oil,” Annals of the American Thoracic Society 13 (2016): 991–992, https://doi.org/10.1513/AnnalsATS.201602‐101LE.
A. Timmerman, M. Balcaen, V. Coopman, M. Degreef, E. Pottie, and C. P. Stove, “Activity‐Based Detection of Synthetic Cannabinoid Receptor Agonists in Plant Materials,” Harm Reduction Journal 21 (2024): 1–11, https://doi.org/10.1186/s12954‐024‐01044‐4.
M. H. Deventer, K. Van Uytfanghe, I. M. J. Vinckier, F. Reniero, C. Guillou, and C. P. Stove, “A New Cannabinoid Receptor 1 Selective Agonist Evading the 2021 “China Ban”: ADB‐FUBIATA,” Drug Testing and Analysis 14 (2022): 1639–1644, https://doi.org/10.1002/dta.3285.
E. Sparkes, E. A. Cairns, R. C. Kevin, et al., “Structure–Activity Relationships of Valine, Tert‐Leucine, and Phenylalanine Amino Acid‐Derived Synthetic Cannabinoid Receptor Agonists Related to ADB‐BUTINACA, APP‐BUTINACA, and ADB‐P7AICA,” RSC Medicinal Chemistry 13 (2022): 156–174, https://doi.org/10.1039/D1MD00242B.
L. Janssens, K. Van Uytfanghe, J. Williams, K. Hering, D. Iula, and C. P. Stove, “Investigation of the Intrinsic Cannabinoid Activity of Hemp‐Derived and Semisynthetic Cannabinoids With β‐arrestin2 Recruitment Assays‐and How This Matters for the Harm Potential of Seized Drugs,” Archives of Toxicology 98 (2024): 2619–2630, https://doi.org/10.1007/s00204‐024‐03769‐4.